Warning Letter — Rohto Pharmaceutical Co., Ltd.
The FDA issued a Warning Letter to Rohto Pharmaceutical Co., Ltd. following an inspection by the Center for Drug Evaluation and Research (CDER).
This affects Rohto Pharmaceutical Co., Ltd., its manufacturing facilities, and personnel responsible for quality management and regulatory compliance.
A Warning Letter from CDER indicates that the agency has identified significant violations of regulatory requirements, which may include Current Good Manufacturing Practice (CGMP) deviations. This action suggests that the firm's previous responses to inspectional observations were insufficient, potentially leading to import alerts or the withholding of new drug approvals until the violations are corrected.
Regulatory and quality teams should conduct a comprehensive review of manufacturing site compliance and documentation standards. Immediate assessment of internal audit findings and remediation of identified gaps is necessary to address the concerns raised in the Warning Letter.
FDA Warning Letter issued to: Rohto Pharmaceutical Co., Ltd.. 10/14/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/rohto-pharmaceutical-co-ltd-733215-10142026
Open in openFDA / FDA.gov